Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rong-zheng Ran"'
Autor:
Jun Chen, Xiao-Lu Lin, Cong Zhuangzhi, Yong-Jie Zhang, Rong-zheng Ran, Tan Weifeng, Hai Zhang, Guoqing Zhang, Fan Mingming, Longjiu Cui
Publikováno v:
Experimental Cell Research. 378:66-75
Liver cancer stem cells (CSCs) contribute to tumorigenesis, progression, drug resistance and recurrence of hepatocellular carcinoma (HCC). However, the underlying mechanism for the propagation of liver CSCs remains unclear. Herein, we observed low ex
Autor:
Jun Chen, Rong-zheng Ran, Cong Zhuangzhi, Weifeng Tan, Fan Mingming, Xiao-Lu Lin, Yong-Jie Zhang, Guoqing Zhang, Longjiu Cui, Hai Zhang
Publikováno v:
Experimental Cell Research. 395:112183
Autor:
Junliang Deng, Xinwei Yang, Xiaoqing Jiang, Weifeng Tan, Guangwei Du, Longjiu Cui, Rong-zheng Ran, Jingquan He
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Hepatocellular carcinoma with bile duct tumor thrombus (BDTT) is a malignant disease. The most commonly used diagnosis methods for BDTT are MRCP/ERCP, ultrasonic diagnosis or CT scan. However, BDTT is often misdiagnosed as other bile duct diseases, s
Autor:
Chen Liu, Xiaoqing Jiang, Sui-yi Liu, Baihe Zhang, Wei-feng Tan, Xiangji Luo, Feng Shen, Rong-zheng Ran, Hao-yu Yang, Wu Mengchao, Bin Yi
Publikováno v:
Academic Journal of Second Military Medical University. 33:411-415
Autor:
Pei-ning Yan, Rong-zheng Ran, Bin Yi, Qingbao Cheng, Xiangji Luo, Xiaoqing Jiang, Baihe Zhang, Jinghan Wang, Chen Liu
Publikováno v:
European Journal of Surgical Oncology (EJSO). 38:1197-1203
Purpose To identify prognostic predictors for overall survival of patients with hilar cholangiocarcinoma of Bismuth type III and IV (HCBT34), and to determine survival benefit and safety of total caudate lobectomy (TCL) in a Chinese centre. Methods F
Autor:
Chen Liu, Meng-Chao Wu, Pei-ning Yan, Xiangji Luo, Baihe Zhang, Yinghe Qiu, Zhiquan Qiu, Xiaoqing Jiang, Wan Yee Lau, Weifeng Tan, Rong-zheng Ran, Feiling Feng, Bing Yi, Jinghan Wang, Yong Yu
Publikováno v:
Acta Pharmacologica Sinica. 31:1643-1648
To determine the efficacy and toxicities of sorafenib in the treatment of patients with multiple recurrences of hepatocellular carcinoma (HCC) after liver transplantation in a Chinese population. Twenty patients with multiple recurrences of HCC after